Moderna shows lasting vaccine efficacy and hope for boosters

14 April 2021

East Coast, USA-based mRNA specialist Moderna (Nasdaq: MRNA) has announced positive clinical trial news from its coronavirus vaccine program.

The firm said its vaccine mRNA-1273, which is approved and in use in multiple jurisdictions including in the UK, USA and Europe, retained a high level of efficacy after six months.

The data also reconfirm the previously-reported high level of vaccine efficacy starting two weeks after the second dose - 90% against all cases of COVID-19, and greater than 95% against severe cases.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK